Quantcast

Latest Cetuximab Stories

2014-04-08 08:32:31

Additional preclinical data highlights the pharmacologic properties of PEGPH20 SAN DIEGO, April 8, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that two scientific poster presentations on the pharmacology of PEGPH20 will be made at the American Association for Cancer Research (AACR) annual meeting being held in San Diego. The first presentation includes preclinical data showing that treatment of tumors with PEGPH20 enhances the action of...

2014-04-03 12:30:35

LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth SummaryGBI Research, has released the pharma report "Monoclonal...

2014-03-17 08:29:15

Company leveraging the scalability of its proprietary platform and next generation sequencing to introduce a full line of multiplexed urine-based oncogene mutation assays with superb sensitivity SAN DIEGO, March 17, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that it has released its first multiplexed oncogene mutation assay, integrating the Company's proprietary sample preparation and primer technologies with...

2014-03-11 23:22:25

UVA study’s surprising finding: Direct treatment of tumor prolongs survival. Charlottesville, VA (PRWEB) March 11, 2014 Contrary to the standard approach to treating metastatic prostate cancer, direct treatment of the primary tumor appears to prolong survival significantly, a new study suggests. The surprising findings have prompted the researchers to launch clinical trials that could upend the accepted treatment of the disease. Prostate Cancer Survival Rate Prostate cancer is the most...

2014-03-04 12:26:52

Incentives for Pathway Compliance, Reduced Hospitalization are Changing Treatment, According to Findings from Decision Resources Group BURLINGTON, Mass., March 4, 2014 /PRNewswire/ -- Decision Resources Group finds that the increasing use of clinical pathway programs, accountable care organizations (ACOs) and bundled payments is changing the prescribing of oncology drugs in the treatment of colorectal cancer and renal cell carcinoma. As more payers and oncology practices adopt pathways,...

2014-02-20 08:32:02

Data Support Ongoing Randomized Phase 2 Study in Recurrent or Metastatic Head and Neck Cancer SEATTLE, Feb. 20, 2014 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc. announced today the presentation of clinical data of VTX-2337, a cancer immunotherapy, in combination with cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck cancer (SCCHN) at the 2014 Multidisciplinary Head and Neck Cancer Symposia in Scottsdale, Arizona. Results indicate that the...

2014-02-20 04:21:29

WHIPPANY, N.J., Feb. 20, 2014 /PRNewswire/ -- Bayer HealthCare today announced that the company has begun to enroll patients in the COAST trial studying Stivarga(®) (regorafenib) tablets in colorectal cancer (CRC) patients with resected liver metastases. The randomized, double-blind, placebo-controlled Phase III trial is designed to determine the effects of Stivarga as adjuvant treatment following surgical removal of liver metastases.(1) "Patients with more advanced colorectal cancer often...

2014-02-14 08:26:33

Clinical and Regulatory Plans for Two Lead Products Announced SAN DIEGO, Feb. 14, 2014 /PRNewswire/ -- MultiVir, a leader in gene therapies for cancer treatment, presented to the investment community at the Leerink Global Healthcare Conference. Highlights of the presentation included an overview of the development plans for the company's two lead products which are supported by strong pre-clinical and clinical data. MultiVir's adenoviral p53 (Ad-p53) and adenoviral interleukin 24...

2014-01-30 12:28:48

International studies demonstrate importance of comprehensive tumor profiling for poor-prognosis cancer patients IRVING, Texas, Jan. 30, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, will present two tumor profiling studies at the 2014 Genitourinary Cancers Symposium held this week in San Francisco, Calif. Through use of the company's comprehensive tumor profiling service, Caris Molecular Intelligence,...

2014-01-30 12:28:09

AUSTIN, Texas, Jan. 30, 2014 /PRNewswire/ -- XBiotech announced today that its collaboration with the European Medicines Agency (EMA) has resulted in establishment of a regulatory path for Xilonix(TM) registration in the European Union for the treatment of colorectal cancer. XBiotech AG will soon launch its Phase III registration study in Europe to evaluate Xilonix in patients with treatment-resistant colorectal cancer. Cancer treatment centers in at least 6 countries will be involved...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related